SYRE — Spyre Therapeutics Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapMomentum Trap

Annual balance sheet for Spyre Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	—	—	—	—	—
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	71.9	146	93.1	55.7	339
Net Total Receivables	—	—	0.815	0.375	0
Prepaid Expenses
Total Current Assets	74.5	150	98.9	62.3	342
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	7.17	9.94	9.15	7.25	0
Other Long Term Assets
Total Assets	83.2	162	110	71.1	342
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	18.4	16.4	20.1	14.7	32
Capital Lease Obligations
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	23.1	21.8	26	20.8	73.3
Redeemable Preferred Stock
Non Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	60.1	140	83.9	50.3	269
Total Liabilities & Shareholders' Equity	83.2	162	110	71.1	342
Total Common Shares Outstanding
Total Preferred Shares Outstanding